CSL Stock

CSL Total Assets

The Total Assets of CSL (CSL.AX) as of Sep 15, 2026 is 33.63 B USD. In the previous year, Total Assets was 39.40 B USD — a change of -14.65% (lower).

Total Assets

33.63 BUSD

YoY

-14.65%

Last updated:

Total Assets of CSL is 2026 33.63 B USD. Total Assets of CSL was 2025 39.40 B USD. It decreases by -14.65% lower compared to the previous year.

The CSL Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2019
12.27 B USD
Jan 1, 2020
15.46 B USD
Jan 1, 2021
18.16 B USD
Jan 1, 2022
41.22 B USD
Jan 1, 2023
54.43 B USD
Jan 1, 2024
38.02 B USD
Jan 1, 2025
39.40 B USD
Jan 1, 2026
33.63 B USD
The CSL Total Assets history
YEARTotal AssetsYoY
33.63 BUSD-14.65%
39.40 BUSD+3.63%
38.02 BUSD-30.15%
54.43 BUSD+32.05%
41.22 BUSD+127.02%
18.16 BUSD+17.42%
15.46 BUSD+26.07%
12.27 BUSD+14.28%
10.73 BUSD+17.66%
9.12 BUSD+20.39%
7.58 BUSD+55.68%
4.87 BUSD-22.46%
6.28 BUSD
Access this data via the Eulerpool API

CSL Stock analysis

What does CSL do? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CSL stock

Total Assets of CSL is 33.63 B USD in 2026.

Total Assets of CSL changed from 39.40 B USD to 33.63 B USD, representing a -14.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets CSL since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's CSL historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — CSL

All Key Metrics — CSL